No Data
No Data
Hunan Jiudian Pharmaceutical (300705.SZ): Withdrawal of pharmaceutical registration application.
On August 11, Gelunhui reported that Hunan Jiudian Pharmaceutical Co., Ltd. (hereinafter referred to as the company) recently submitted a report to the National Medical Products Administration to withdraw the registration application for Jiaoqi Shexing Nengjiao Tiegao. Jiaoqi Shexing Nengjiao Tiegao is a local transdermal preparation developed by the company based on clinical experience and has the effects of warming meridian, dispelling cold, promoting blood circulation, and relieving pain, used for Bi syndrome caused by cold coagulation and blood stasis, with symptoms such as joint pain, tenderness, local cold, warm pain relief, poor joint mobility, stiffness and swelling, and osteoarthritis with the above symptoms. Jiaoqi Shexing Nengjiao Tiegao was approved in April 2006.
Is Hunan Jiudian Pharmaceutical (SZSE:300705) Using Too Much Debt?
CICC Starts Hunan Jiudian Pharmaceutical at Outperform With 32 Yuan Price Target
Hunan Jiudian Pharmaceutical (300705.SZ): So far, the area where Loxoprofen Sodium Gel Patches have implemented centralized procurement includes 19 regions.
On July 25th, 2024, Hunan Jiudian Pharmaceutical (300705.SZ) accepted a specific object survey and was asked about "the execution of local alliance joint procurement of Loxoprofen Sodium Gel Patch, how is the current situation?" The company replied that as of now, Loxoprofen Sodium Gel Patch has been executed in 19 regions under joint procurement. From the current execution effect, the company has achieved a virtuous cycle of price for quantity, further consolidating the product's competitive position in the market.
Is Hunan Jiudian Pharmaceutical Co., Ltd.'s (SZSE:300705) Latest Stock Performance Being Led By Its Strong Fundamentals?
Hunan Jiudian Pharmaceutical's (SZSE:300705) Five-year Earnings Growth Trails the 37% YoY Shareholder Returns
No Data